The Menarini Group
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From The Menarini Group
Strong oncology sales have driven the company’s revenues to new heights, keeping it on target to meet its yearly revenue guidance.
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
User fee goal dates are coming up in October for more than 15 applications, according to the Pink Sheet’s US FDA Performance Tracker.
Congenital athymia treatment Rethymic (RVT-802) is still under FDA review, with an 8 October user fee goal date, but FDA announced the regenerative medicine product had earned a rare pediatric disease priority review voucher; agency says the notice was published in error and will be withdrawn.
In Vitro Diagnostics
- Chemistry, Immunoassay
- Glucose Testing
- Hematology, Coagulation
- Urine-based Testing
- Other Names / Subsidiaries
- A. Menarini Diagnostics S.r.l.
- Berlin Chemie AG
- Invida Group Private Limited
- Menarini Asia-Pacific Holdings (Menarini AP)